Remdesivir for COVID‐19 pneumonia in patients with severe chronic kidney disease: A Case series and review of the literature
journal contribution
submitted on 2023-03-15, 08:02 and posted on 2023-03-16, 06:21 authored by Ahmad Al Bishawi, Hamad Abdel Hadi, Eman Elmekaty, Musaed Al Samawi, Arun Nair, Mohammed Abou Kamar, Muna Al Maslamani, Alaaeldin AbdelmajidRemdesivir was the first antiviral agent to receive FDA authorization for severe COVID-19 management, which restricts its use with severe renal impairment due to concerns that active metabolites might accumulate, causing renal toxicities. With limited treatment options, available evidence on such patient groups is important to assess for future safety.
Other Information
Published in: Clinical Case Reports
License: http://creativecommons.org/licenses/by/4.0/
See article on publisher's website: http://dx.doi.org/10.1002/ccr3.5467
History
Language
- English
Publisher
WileyPublication Year
- 2022
Institution affiliated with
- Hamad Medical Corporation
